| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75b30ff8273a54b655e5eb2eed62b4b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_945bffeca2acbeef7522ad0b0b67d61f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38ddf07b15d338a1f8f184ec80db6ab0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_490ebaf9753aaa24ef094494f8624b0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c92d9e5c08b83ba2027e9a6bf251b12b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c17ca1b539a7e24cdc0ea53597054b4a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 |
| filingDate |
2008-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ab72c294ee5766499bc643b24ce52c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78106a1e6dafdb86a305773d0ba4e0ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4feeb47b4b056559f747f79aa5a3c9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d18915800d333d6a21ca6f7bdb17a9bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_172de72096c83caffad83be3df86e68b |
| publicationDate |
2008-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008124102-A2 |
| titleOfInvention |
Ara-c in combination with a cytokine-secreting cell and use thereof |
| abstract |
The present invention provides improved method of cancer therapy in a mammal. More particularly, the invention is concerned with systems comprising cytosine arabinoside (AraC) and a cytokine-expressing cancer immunotherapy composition and methods of administering the combination to cancer patients in order to generate an immune response against the cancer and provide treatment with therapeutic efficacy that is an improvement relative to administration of AraC or the cytokine-expressing cancer immunotherapy composition alone as a monotherapy. |
| priorityDate |
2007-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |